Medpage is a good site to check out. This month it gives a good review of several of the articles presented at the San Antonio Breast Cancer Symnposium. Over twenty articles are available for review and free CME credit is given after you read each one (just answer two or three questions based on what you read). A couple of highlights:
1. As breast conservation therapy has increased, the use of breast irradiation has not risen accordingly; troubling in that lack of radiation after lumpectomy doubles your risk of recurrence.
2. An interesting study detailing the arbitrary five year cutoff for Tamoxifen; ten years may be beneficial. Of course, with the enthusiasm now for aromatase inhibitors, the argument may become obsolete.
3. Speaking of aromatase inhibitors, there's an article that describes an extended benefit past completion of treatment with Arimidex.
4. A good meta-analysis on the negligible benefits of high dose chemotherapy for advanced breast cancer.
5. Another study that questions the use of antracyclines (long a primary agent) as adjuvant therapy for all women with breast cancer.